Teladoc Health (NYSE:TDOC) Given New $6.00 Price Target at TD Cowen

Teladoc Health (NYSE:TDOC) had its price target cut by research analysts at TD Cowen from $8.00 to $6.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “hold” rating on the health services provider’s stock. TD Cowen’s price target points to a potential upside of 12.89% from the company’s previous close.

TDOC has been the topic of several other research reports. BMO Capital Markets started coverage on Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price target on the stock. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Thursday. Citigroup decreased their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Friday, January 9th. Wells Fargo & Company lowered their price target on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.11.

Teladoc Health Stock Up 14.3%

Teladoc Health stock traded up $0.67 during mid-day trading on Thursday, reaching $5.32. 14,644,582 shares of the company’s stock were exchanged, compared to its average volume of 6,787,662. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. Teladoc Health has a twelve month low of $4.40 and a twelve month high of $10.02. The company has a market cap of $943.25 million, a P/E ratio of -4.15 and a beta of 2.12. The company has a fifty day moving average of $6.06 and a 200-day moving average of $7.22.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The business had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The company’s revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Sell-side analysts expect that Teladoc Health will post -1.16 EPS for the current year.

Insider Activity at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. This represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 33,288 shares of company stock worth $251,684. Corporate insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH increased its position in Teladoc Health by 189.2% during the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Teladoc Health in the second quarter valued at approximately $2,722,000. Jupiter Asset Management Ltd. purchased a new position in shares of Teladoc Health during the third quarter worth approximately $7,576,000. Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in shares of Teladoc Health by 23.1% in the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 212,933 shares of the health services provider’s stock valued at $1,841,000 after acquiring an additional 39,956 shares during the period. Finally, Empowered Funds LLC acquired a new position in shares of Teladoc Health in the 2nd quarter valued at $5,040,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results beat expectations — Teladoc reported revenue of $642.3M (above $635.3M consensus) and EPS of ($0.14), topping estimates. The beat reduces near‑term earnings uncertainty and provides proof of stabilization after prior losses. Q4 sales surprise
• Positive Sentiment: Conference call highlighted growth in Integrated Care and strategic repositioning of BetterHelp — management emphasized areas of improving unit economics and product focus that could drive margin recovery over time. Investors often reward visible operational progress even when near‑term guidance is cautious. Earnings call highlights
• Neutral Sentiment: Deeper metric readouts available — analysts and outlets (e.g., Zacks) are parsing subscriber, utilization and margin metrics to assess sustainability of the beat; these details will influence revisions to models but don’t yet change the headline picture. Zacks analysis
• Negative Sentiment: Forward guidance disappointed — Q1 2026 EPS guidance of -0.450 to -0.350 and FY 2026 EPS of -1.100 to -0.700 both sit below consensus; Q1 revenue guidance ($598M–$620M) is also below Street estimates. This increases near‑term downside risk and keeps profitability recovery uncertain. Guidance details
• Negative Sentiment: Analysts cut price targets — Wells Fargo and Stifel reduced targets from $8 to $6 and kept neutral/hold stances, signaling tempered expectations for upside and contributing to mixed sell‑side sentiment. Benzinga

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.